The modular network structure of the mutational landscape of Acute Myeloid Leukemia

dc.contributor.authorIbánez, Mariam
dc.contributor.authorCarbonell Caballero, José
dc.contributor.authorSuch, Esperanza
dc.contributor.authorGarcía Alonso, Luz
dc.contributor.authorLiguori, Alessandro
dc.contributor.authorLópez Pavía, María
dc.contributor.authorLlop, Marta
dc.contributor.authorAlonso, Carmen
dc.contributor.authorBarragán, Eva
dc.contributor.authorGómez Seguí, Inés
dc.contributor.authorNeef, Alexander
dc.contributor.authorHervás, David
dc.contributor.authorMontesinos, Pau
dc.contributor.authorSanz, Guillermo
dc.contributor.authorSanz, Miguel Angel
dc.contributor.authorDopazo, Joaquín
dc.contributor.authorCervera, José
dc.date.accessioned2020-11-17T13:23:06Z
dc.date.available2020-11-17T13:23:06Z
dc.date.issued2018-10-10
dc.date.updated2020-11-11T17:40:02Z
dc.description.abstractAcute myeloid leukemia (AML) is associated with the sequential accumulation of acquired genetic alterations. Although at diagnosis cytogenetic alterations are frequent in AML, roughly 50% of patients present an apparently normal karyotype (NK), leading to a highly heterogeneous prognosis. Due to this significant heterogeneity, it has been suggested that different molecular mechanisms may trigger the disease with diverse prognostic implications. We performed whole-exome sequencing (WES) of tumor-normal matched samples of de novo AML-NK patients lacking mutations in NPM1, CEBPA or FLT3-ITD to identify new gene mutations with potential prognostic and therapeutic relevance to patients with AML. Novel candidate-genes, together with others previously described, were targeted resequenced in an independent cohort of 100 de novo AML patients classified in the cytogenetic intermediate-risk (IR) category. A mean of 4.89 mutations per sample were detected in 73 genes, 35 of which were mutated in more than one patient. After a network enrichment analysis, we defined a single in silico model and established a set of seed-genes that may trigger leukemogenesis in patients with normal karyotype. The high heterogeneity of gene mutations observed in AML patients suggested that a specific alteration could not be as essential as the interaction of deregulated pathways.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid30303964
dc.identifier.urihttps://hdl.handle.net/2445/172138
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0202926
dc.relation.ispartofPLoS One, 2018, vol. 13, num. 10, p. e0202926
dc.relation.urihttps://doi.org/10.1371/journal.pone.0202926
dc.rightscc by (c) Ibáñez et al., 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationLeucèmia mieloide
dc.subject.classificationGenètica
dc.subject.otherMyeloid leukemia
dc.subject.otherGenetics
dc.titleThe modular network structure of the mutational landscape of Acute Myeloid Leukemia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
IbanezM.pdf
Mida:
4.6 MB
Format:
Adobe Portable Document Format